Syneos Health (SYNH) Sets New 1-Year High at $55.01

Syneos Health Inc (NASDAQ:SYNH) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $55.01 and last traded at $55.10, with a volume of 13296 shares changing hands. The stock had previously closed at $54.85.

SYNH has been the subject of several analyst reports. ValuEngine upgraded shares of Syneos Health from a “hold” rating to a “buy” rating in a report on Saturday, November 10th. Zacks Investment Research lowered shares of Syneos Health from a “buy” rating to a “hold” rating in a report on Saturday, November 17th. Finally, SunTrust Banks lowered their price target on shares of Syneos Health to $55.00 and set a “buy” rating for the company in a report on Wednesday, December 19th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Syneos Health presently has an average rating of “Buy” and an average target price of $53.44.

The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.97 and a current ratio of 0.97. The firm has a market capitalization of $5.66 billion, a PE ratio of 28.39, a P/E/G ratio of 1.53 and a beta of 1.51.

In related news, General Counsel Jonathan Olefson acquired 750 shares of the stock in a transaction dated Monday, December 17th. The stock was bought at an average price of $41.27 per share, for a total transaction of $30,952.50. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Alistair Macdonald sold 8,143 shares of Syneos Health stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $53.00, for a total transaction of $431,579.00. The disclosure for this sale can be found here. 0.57% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in SYNH. JPMorgan Chase & Co. increased its stake in shares of Syneos Health by 1,589.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,319,875 shares of the company’s stock valued at $68,040,000 after acquiring an additional 1,241,754 shares in the last quarter. BlackRock Inc. increased its stake in shares of Syneos Health by 10.3% in the 3rd quarter. BlackRock Inc. now owns 8,035,926 shares of the company’s stock valued at $414,252,000 after acquiring an additional 751,050 shares in the last quarter. Vanguard Group Inc increased its stake in shares of Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after acquiring an additional 624,991 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc. now owns 6,914,223 shares of the company’s stock valued at $356,429,000 after acquiring an additional 624,991 shares in the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in shares of Syneos Health by 3,641.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 473,191 shares of the company’s stock valued at $24,393,000 after acquiring an additional 460,545 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Syneos Health (SYNH) Sets New 1-Year High at $55.01” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2019/02/20/syneos-health-synh-sets-new-1-year-high-at-55-01.html.

Syneos Health Company Profile (NASDAQ:SYNH)

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Featured Story: What economic reports are most valuable to investors?

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit